PGGM Investments Has $6.94 Million Stock Holdings in Agilent Technologies, Inc. (NYSE:A)

PGGM Investments raised its holdings in Agilent Technologies, Inc. (NYSE:A) by 4.7% in the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 51,634 shares of the medical research company’s stock after acquiring an additional 2,330 shares during the quarter. PGGM Investments’ holdings in Agilent Technologies were worth $6,937,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of A. Massachusetts Financial Services Co. MA increased its holdings in Agilent Technologies by 3.5% in the third quarter. Massachusetts Financial Services Co. MA now owns 15,589,874 shares of the medical research company’s stock valued at $2,314,784,000 after purchasing an additional 525,214 shares during the period. State Street Corp grew its position in shares of Agilent Technologies by 1.2% in the 3rd quarter. State Street Corp now owns 12,819,897 shares of the medical research company’s stock valued at $1,903,498,000 after buying an additional 158,175 shares during the last quarter. Geode Capital Management LLC grew its position in shares of Agilent Technologies by 0.4% in the 3rd quarter. Geode Capital Management LLC now owns 6,948,679 shares of the medical research company’s stock valued at $1,028,241,000 after buying an additional 30,610 shares during the last quarter. Cantillon Capital Management LLC raised its position in shares of Agilent Technologies by 0.5% during the fourth quarter. Cantillon Capital Management LLC now owns 3,316,557 shares of the medical research company’s stock worth $445,546,000 after acquiring an additional 17,627 shares during the last quarter. Finally, Van ECK Associates Corp lifted its stake in shares of Agilent Technologies by 8.7% in the fourth quarter. Van ECK Associates Corp now owns 3,235,263 shares of the medical research company’s stock worth $434,625,000 after acquiring an additional 258,358 shares during the period.

Insider Buying and Selling at Agilent Technologies

In other Agilent Technologies news, CEO Padraig Mcdonnell sold 1,911 shares of the firm’s stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $150.00, for a total transaction of $286,650.00. Following the transaction, the chief executive officer now directly owns 39,652 shares in the company, valued at approximately $5,947,800. This trade represents a 4.60 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the stock. Sanford C. Bernstein decreased their target price on shares of Agilent Technologies from $140.00 to $135.00 and set a “market perform” rating for the company in a research report on Tuesday, November 26th. Robert W. Baird decreased their price objective on shares of Agilent Technologies from $161.00 to $159.00 and set an “outperform” rating for the company in a research report on Thursday, February 27th. Bank of America dropped their target price on shares of Agilent Technologies from $153.00 to $150.00 and set a “neutral” rating on the stock in a report on Friday, December 13th. Barclays upgraded Agilent Technologies from an “underweight” rating to an “equal weight” rating and increased their price target for the stock from $135.00 to $145.00 in a report on Monday, February 10th. Finally, Citigroup boosted their price objective on Agilent Technologies to $165.00 and gave the company a “buy” rating in a research note on Thursday, December 19th. Seven investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $146.15.

Agilent Technologies Trading Down 2.2 %

NYSE A opened at $117.21 on Friday. Agilent Technologies, Inc. has a 52 week low of $117.17 and a 52 week high of $155.35. The business has a 50 day moving average price of $138.54 and a 200-day moving average price of $138.13. The company has a quick ratio of 1.66, a current ratio of 2.20 and a debt-to-equity ratio of 0.56. The company has a market cap of $33.42 billion, a price-to-earnings ratio of 26.94, a P/E/G ratio of 3.36 and a beta of 1.11.

Agilent Technologies (NYSE:A) last announced its quarterly earnings results on Wednesday, February 26th. The medical research company reported $1.31 EPS for the quarter, beating analysts’ consensus estimates of $1.27 by $0.04. Agilent Technologies had a net margin of 19.27% and a return on equity of 25.56%. The business had revenue of $1.68 billion during the quarter, compared to analyst estimates of $1.67 billion. As a group, equities analysts expect that Agilent Technologies, Inc. will post 5.57 earnings per share for the current fiscal year.

Agilent Technologies Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, April 23rd. Investors of record on Tuesday, April 1st will be given a $0.248 dividend. The ex-dividend date of this dividend is Tuesday, April 1st. This represents a $0.99 annualized dividend and a yield of 0.85%. Agilent Technologies’s payout ratio is 22.76%.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.